Hepatosplenic T-cell lymphomas (HSTL) are a rare subgroup of peripheral T-cell lymphomas that usually express the gd TCR.
/l). The pathological findings are summarised in Figure 1 .
She was treated with one cycle of FAD chemotherapy (fludarabine, doxorubicin, dexamethasone), one cycle of CHOP chemotherapy, followed by five cycles of fludarabine, cyclophosphamide and dexamethasone. Although she had a transient response to each treatment, her hepatomegaly, lymphocytosis and B symptoms returned approximately 3 weeks after the commencement of each course. She went on to receive salvage therapy with ESHAP (etopside, methylprednisolone, cisplatin, cytarabine) followed by mini-BEAM (carmustine, etoposide, cytarabine, melphalan). She achieved a good partial response with complete resolution of her hepatomegaly by CT criteria, but with persistent low-volume marrow involvement.
The patient had no sibling match and proceeded to a T-cell replete, fully HLA-matched unrelated donor transplant (unmanipulated bone marrow) 3 weeks after her last treatment. The conditioning consisted of cyclophosphamide (120 mg/kg) and total body irradiation (1200 cGy in six fractions), with short-course methotrexate and cyclosporin as graft-versus-host disease (GVHD) prophylaxis. Both donor and patient had serological evidence of previous cytomegalovirus (CMV) infection.
The post-transplant course was complicated by the development of acute grade IV GVHD, involving skin (stage 3), liver (stage 4) and gut (stage 4). The last manifested as gastro-intestinal haemorrhage, which became difficult to control despite appropriate blood product support, infusional pantoprazole and aprotinin, but finally responded to recombinant factor VIIa treatment.
By day þ 58 she developed tender hepatomegaly, jaundice and palpable crepitus over the right upper quadrant with an audible liver rub. A trans-jugular liver biopsy confirmed hepatic GVHD, without evidence of lymphoma. She was commenced on methylprednisolone without apparent benefit, and subsequently received antithymocyte globulin. Her bilirubin peaked at 300 g/dl on day þ 71, but gradually improved to normal by day þ 104. Remarkably, there was no evidence of CMV reactivation as assessed by weekly quantitative PCR monitoring.
She had mild limited chronic skin GVHD for several months. Complete remission was confirmed by both conventional (CT) and functional (positron emission tomography (PET) imaging using [F]fluorodeoxyglucose), as well as a repeat bone marrow and liver biopsy at 24 months. She remains in complete remission, 54 months after diagnosis, and 40 months since transplant. She is currently pregnant.
A variety of treatment modalities have been used for both ab and gd HSTL. While patients often attain a transient response to chemotherapy, almost all patients relapse and succumb to their disease within a period of months. In one series, for instance, all 19 patients who received CHOP-like chemotherapy for gd HSTL subsequently died, despite nine of them initially achieving a complete response. 2 Similarly, all patients who received conventional dose chemotherapy for ab HSTL have died from disease progression. [3] [4] [5] More intensive approaches have had some success, with one patient reported to be in remission 58 months after treatment with the intensive acute lymphoblastic leukaemia Memorial Sloan-Kettering-New York-II protocol (MSK-NY-II). 3 Only two patients have reportedly undergone autologous bone marrow transplantation; one was in remission at 24 months, and the other died with disease 15 months post transplant. 3 To our knowledge, this is only the third reported case of allogeneic haematopoietic stem cell transplantation for ab HSTL. Two of the three patients are in long-term remission, while the third was transplanted with progressive disease, did not respond and died 2 months later. 6, 7 The experience of allogeneic transplantation in cases of gd HSTL is also limited. Of the 12 reported cases (Table 1) , six patients achieved a complete remission, two of whom relapsed and died from disease 13 and 15 months later. 1, 2, [8] [9] [10] [11] [12] [13] Four patients died of treatment-related causes, two with cerebral toxoplasmosis. The other four patients remained in remission, although the follow-up was short.
The role of high-dose therapy with autologous transplantation warrants further exploration, although it must be recognised that patients usually have marrow infiltration at diagnosis. Allogeneic transplantation allows similar dose escalation and the potential benefit of a graft that is free from tumour contamination. Furthermore, a case of complete clinical and molecular remission following donor lymphocyte infusion on relapse of ab HSTL provides proof of principle of an allogeneic graftversus-tumour effect. 6 It is possible that the development of severe GVHD in our patient was of eventual therapeutic benefit.
As disease relapse often occurs early following conventional dose chemotherapy and the curative potential of such approaches is currently questionable, early consolidative allogeneic transplant must be seriously considered as a therapeutic option in these patients. Figure 1 The splenic red pulp was diffusely expanded and permeated by a pleomorphic population of medium-sized lymphocytes, some with irregular nuclear contours. There was marked intrasinusoidal infiltration (a). The lymphocytes showed strong immunohistochemical staining for CD3 (b), but were CD4, CD5, CD8, and CD 20 negative. Tumour cells showed positive staining for CD56 (c), T-cell intracellular antigen-1 (TIA) and the TCR beta chain (d). A monoclonal rearrangement of the TCR gamma locus was identified by polymerase chain reaction (PCR). Flow cytometry of the peripheral blood identified the circulating lymphocytes as positive for CD3, CD38, CD56 and TCRab. The bone marrow trephine revealed striking intrasinusoidal infiltration with atypical lymphocytes (e), with positive staining for CD3. A dominant rearrangement of the TCR gamma locus was confirmed by PCR. Conventional cytogenetics of the bone marrow showed a normal 46XX karyotype, and fluorescence in situ hybridisation (FISH) for isochrome 7q was negative. 
